During the recent session, Standard BioTools Inc (NASDAQ:LAB)’s traded shares were 0.48 million, with the beta value of the company hitting 1.50. At the last check today, the stock’s price was $1.08, reflecting an intraday loss of -1.38% or -$0.01. The 52-week high for the LAB share is $2.41, that puts it down -123.15 from that peak though still a striking 14.81% gain since the share price plummeted to a 52-week low of $0.92. The company’s market capitalization is $408.31M, and the average trade volume was 1.27 million shares over the past three months.
Standard BioTools Inc (LAB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.67. LAB has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it.
Standard BioTools Inc (NASDAQ:LAB) trade information
Standard BioTools Inc (LAB) registered a -1.38% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.38% in intraday trading to $1.08, hitting a weekly high. The stock’s 5-day price performance is 2.38%, and it has moved by 2.38% in 30 days. Based on these gigs, the overall price performance for the year is -49.05%.
The consensus price target of analysts on Wall Street is $3.25, which implies an increase of 66.77% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3.25 and $3.25 respectively. As a result, LAB is trading at a discount of -200.93% off the target high and -200.93% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 11.61%. While earnings are projected to return 55.77% in 2025, the next five years will return 66.44% per annum.
LAB Dividends
Standard BioTools Inc is due to release its next quarterly earnings on 2025-May-06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Standard BioTools Inc (NASDAQ:LAB)’s Major holders
Standard BioTools Inc insiders own 1.38% of total outstanding shares while institutional holders control 73.07%, with the float percentage being 74.10%. CASDIN CAPITAL, LLC is the largest shareholder of the company, while 197.0 institutions own stock in it. As of 2024-06-30, the company held over 63.96 million shares (or 17.1782% of all shares), a total value of $113.21 million in shares.
The next largest institutional holding, with 58.65 million shares, is of VIKING GLOBAL INVESTORS LP’s that is approximately 15.7524% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $103.81 million.
